Bio-Techne (TECH) announced an agreement where Mdxhealth (MDXH) will acquire its Exosome Diagnostics business, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory and related assets. Bio-Techne will retain access to the proprietary exosome-based technology for ongoing kit development in its precision diagnostics growth pillar. Under the terms of the agreement, Bio-Techne will receive $5M in MDXH stock combined with future considerations. The transaction is expected to be completed during the first quarter of Bio-Techne’s fiscal 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne price target raised to $58 from $51 at Baird
- Promising Long-Term Growth for Bio-Techne Amidst Current Challenges: A Buy Recommendation by Kyle Boucher
- Bio-Techne resumed with an Overweight at Stephens
- Bio-Techne and Spear Bio partner for ultrasensitive biomarker detection
- Bio-Techne initiated with a Buy at TD Cowen